Singlomics
Beijing
About Singlomics
Singlomics uses single-cell sequencing technology to develop antibody drugs for the treatment of infectious diseases and cancers.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $63.2M
- Last round: Series Unknown (Jul 2023)
- Website: singlomics.com
- Phone: 010-80765087
Industries & Categories
Biotechnology, Health Care, Medical
Canonical: https://fsome.com/organization/singlomics-59274 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.